# | Title | Journal | Year | Citations |
---|
1 | Dissecting components of reward: ‘liking’, ‘wanting’, and learning | Current Opinion in Pharmacology | 2009 | 1,530 |
2 | Vitamin D: modulator of the immune system | Current Opinion in Pharmacology | 2010 | 1,025 |
3 | Antibacterial peptides for therapeutic use: obstacles and realistic outlook | Current Opinion in Pharmacology | 2006 | 901 |
4 | NMDA receptor subunits: function and pharmacology | Current Opinion in Pharmacology | 2007 | 746 |
5 | Role of neurotrophic factors in depression | Current Opinion in Pharmacology | 2007 | 610 |
6 | Novel trends in high-throughput screening | Current Opinion in Pharmacology | 2009 | 550 |
7 | N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency | Current Opinion in Pharmacology | 2007 | 542 |
8 | The mechanisms of action of gabapentin and pregabalin | Current Opinion in Pharmacology | 2006 | 520 |
9 | Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity | Current Opinion in Pharmacology | 2009 | 503 |
10 | Update on the antibiotic resistance crisis | Current Opinion in Pharmacology | 2014 | 501 |
11 | Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises | Current Opinion in Pharmacology | 2008 | 488 |
12 | PD-1/PD-L1 inhibitors | Current Opinion in Pharmacology | 2015 | 483 |
13 | Natural products in anticancer therapy | Current Opinion in Pharmacology | 2001 | 477 |
14 | Reward system and addiction: what dopamine does and doesn’t do | Current Opinion in Pharmacology | 2007 | 463 |
15 | Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression | Current Opinion in Pharmacology | 2002 | 459 |
16 | Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders | Current Opinion in Pharmacology | 2008 | 444 |
17 | GABA-based therapeutic approaches: GABAA receptor subtype functions | Current Opinion in Pharmacology | 2006 | 443 |
18 | Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology | Current Opinion in Pharmacology | 2005 | 438 |
19 | Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine | Current Opinion in Pharmacology | 2005 | 428 |
20 | Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress | Current Opinion in Pharmacology | 2007 | 418 |
21 | Renaissance in antibacterial discovery from actinomycetes | Current Opinion in Pharmacology | 2008 | 413 |
22 | Targeting mTOR signaling for cancer therapy | Current Opinion in Pharmacology | 2003 | 411 |
23 | Mechanism of action of memantine | Current Opinion in Pharmacology | 2006 | 390 |
24 | Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response | Current Opinion in Pharmacology | 2006 | 386 |
25 | The p38 MAP kinase pathway as a therapeutic target in inflammatory disease | Current Opinion in Pharmacology | 2004 | 382 |
26 | Neurobiology of craving, conditioned reward and relapse | Current Opinion in Pharmacology | 2005 | 374 |
27 | Targeting the androgen receptor pathway in prostate cancer | Current Opinion in Pharmacology | 2008 | 371 |
28 | Effects of nicotinic stimulation on cognitive performance | Current Opinion in Pharmacology | 2004 | 357 |
29 | Parathyroid hormone: anabolic and catabolic actions on the skeleton | Current Opinion in Pharmacology | 2015 | 355 |
30 | Histone deacetylases | Current Opinion in Pharmacology | 2003 | 354 |
31 | Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation | Current Opinion in Pharmacology | 2009 | 350 |
32 | Inflammation and cancer: how friendly is the relationship for cancer patients? | Current Opinion in Pharmacology | 2009 | 343 |
33 | Angiotensin-converting enzyme 2 in lung diseases | Current Opinion in Pharmacology | 2006 | 342 |
34 | Targeting death receptors in cancer with Apo2L/TRAIL | Current Opinion in Pharmacology | 2004 | 336 |
35 | Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications | Current Opinion in Pharmacology | 2004 | 326 |
36 | Natural products as a gold mine for arthritis treatment | Current Opinion in Pharmacology | 2007 | 326 |
37 | Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota | Current Opinion in Pharmacology | 2009 | 325 |
38 | microRNAs and the immune response | Current Opinion in Pharmacology | 2009 | 321 |
39 | Monoclonal antibody therapeutics: history and future | Current Opinion in Pharmacology | 2012 | 320 |
40 | Ethanol and brain damage | Current Opinion in Pharmacology | 2005 | 307 |
41 | Glutamate systems in cocaine addiction | Current Opinion in Pharmacology | 2004 | 306 |
42 | ERK2: a logical AND gate critical for drug-induced plasticity? | Current Opinion in Pharmacology | 2007 | 304 |
43 | The role of serotonin receptors in the action of atypical antipsychotic drugs | Current Opinion in Pharmacology | 2011 | 304 |
44 | Gut microbiota, enteroendocrine functions and metabolism | Current Opinion in Pharmacology | 2013 | 300 |
45 | Oxidative stress and mitochondrial dysfunction in glaucoma | Current Opinion in Pharmacology | 2013 | 300 |
46 | Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery | Current Opinion in Pharmacology | 2006 | 294 |
47 | Stress hormones: physiological stress and regulation of metabolism | Current Opinion in Pharmacology | 2009 | 288 |
48 | PCP: from pharmacology to modelling schizophrenia | Current Opinion in Pharmacology | 2005 | 277 |
49 | Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists | Current Opinion in Pharmacology | 2006 | 277 |
50 | Targeting Hsp90: small-molecule inhibitors and their clinical development | Current Opinion in Pharmacology | 2008 | 277 |